

**Amendments to the Claims:**

This listing of claims replaces all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (Currently Amended) [An] A biodegradable barrier network, comprising:
  - a) a cationic polypeptide[.];
  - b) an anionic polypeptide; and
  - c) a pharmaceutically acceptable carrier.
2. (Previously Presented) The biodegradable barrier network according to claim 1, wherein amino acid residues in the cationic polypeptide are selected from the group consisting of amino acid residues R, H, K, synthetic and semisynthetic variants and mixtures thereof.
3. (Previously Presented) The biodegradable barrier network according to claim 2, wherein amino acid residues in the anionic polypeptide are selected from the group consisting of the amino acid residues D, E, synthetic and semisynthetic variants and mixtures thereof.
4. (Previously Presented) The biodegradable barrier network according to claim 1, wherein the amino acid residues within at least one of the polypeptides are of the same type.
5. (Currently Amended) The biodegradable barrier[[],] network according to claim 1, wherein at least one of the polypeptides is linked to one or more amino acid residues, other peptides or other substances.
6. (Previously Presented) The biodegradable barrier network according to claim 1, wherein at least one of the peptides is modified by amidation, esterification, acylation, PEGylation or alkylation.
7. (Currently Amended) The biodegradable network according to claim 1, wherein the peptides have a size of at least 5.000 Da, ~~such as from about 5.000 to about 50.000 Da.~~

8. (Currently Amended) The biodegradable barrier network according to claim 1, wherein the ~~biodegradable network comprises a pharmaceutical~~ pharmaceutically acceptable carrier, ~~such as~~ comprises a diluent or buffer.

9. (Previously Presented) The biodegradable barrier network according to claim 1, wherein the biodegradable network comprises a therapeutic agent such as antimicrobial agents, antiinflammatory agents, cleaning agents, antioxidants, apoptosis modulators, healing agents, fibrogenesis inhibitors, antitumor agents and antibleeding agents.

10. (Original) The biodegradable barrier network according to claim 9, wherein the therapeutic agent is selected from the group comprising of penicillins, cephalosporins, carbacephems, tetracyclines, macrolides, iodine, silver, copper, clorhexidine, acetylsalicylic acid, proteolytic enzymes, vitamins, glutathione, folic acid, curcumin, resveratrol, anthocyanidins, glucocorticosteroids, insulin, dexamethasone, carotenoids, linoleic and conjugated-linoleic acids, melatonin, isothiocyanates, shikonin, solamargine, perifosine, deoxynivalenol, carboxyamido-triazole (CAI), histone deacetylase inhibitors, growth factors, insulin, vitamin E, retinoic acid, herbal components norepinephrine, gelatin, collagen and oxidized cellulose.

11. (Original) An applicator comprising:

a) a cationic polypeptide and a pharmaceutically acceptable carrier;

b) an anionic polypeptide and a pharmaceutically acceptable carrier;

said cationic polypeptide and anionic polypeptide being separated from each other by a separator.

12. (Original) The applicator according to claim 11, wherein the applicator is selected from the group comprising of syringes, one or multi-component sprays, nebulators, plasters, catheters, adhesives, implants and bandages.

13. (Previously Presented) The applicator according to claim 11, wherein the separator is a gelled aqueous solution or a membrane.

14. (Cancel)

15. (Currently Amended) A kit comprising:

- a) a cationic polypeptide and a pharmaceutically acceptable carrier;
- b) an anionic polypeptide and a pharmaceutically acceptable carrier; and
- c) means for administering said cationic and anionic polypeptide.

16. (Cancel)

17. (Previously Presented) The kit according to claim 15, wherein the means is selected from the group comprising of syringes, plasters, catheters, adhesives, implants, bandages, one or multi-component sprays, and nebulators.

18. (Previously Presented) The applicator according to claim 11, comprising a therapeutic agent such as antimicrobial agents, antiinflammatory agents, cleaning agents, antioxidants, apoptosis modulators, healing agents, fibrogenesis inhibitors, antitumor agents and antibleeding agents.

19. (Previously Presented) The applicator or the kit according to claim 18, wherein the therapeutic agent is selected from the group comprising of penicillins, cephalosporins, carbacephems, tetracyclines, macrolides, iodine, silver, copper, clorhexidine, acetylsalicylic acid, proteolytic enzymes, vitamins, glutathione, folic acid, curcumin, resveratrol, epigallocatechin, anthocyanidins, glucocorticosteroids, insulin, dexamethasone, carotenoids, linoleic and conjugated-linoleic acids, melatonin, isothiocyanates, shikonin, solamargine, perifosine, deoxynivalenol, carboxyamido-triazole (CAI), histone deacetylase inhibitors, growth factors, insulin, vitamin E, retinoic acid, herbal components norepinephrine, gelatin, collagen and oxidized cellulose.

20. (Previously Presented) The applicator according to Claim 18, wherein the therapeutic agent is separated from the two polypeptides or mixed with one or both of the polypeptides.

21. (Cancel)

22. (Withdrawn) A method of treating a mammal having an injury, comprising use of the applicator according to claim 11 for creating the biodegradable barrier network.

23. (New) The biodegradable barrier network according to claim 1, wherein the peptides have a size of 5.000 to about 50.000 Da.

**Support for Amendments:**

Claims 1 and 5 are amended to correct typographically errors.

Claim 7 is amended by cancelling the phrase “such as from about 5.000 to about 50.000 Da.” This feature is introduced in new dependent claim 23.

Claim 8 is amended to more clearly state that the pharmaceutically acceptable carrier comprises a diluent or buffer.

Claim 15 is amended to introduce punctuation.

No new matter is introduced by this amendment, and entry thereof is requested. Upon entry, claims 1-13, 15, 17-20, and 22-23 are active in this application.